 |
|
|
|
|
VI. Clinical Pathology Support of Phase II and Phase III Trials |
|
|
|
| |
|
|
|
|
|
A. Views of Investigators on the Use of Local Versus Central Laboratories |
|
|
|
| |
|
|
|
|
|
B. Views of Sponsors on the Use of Multiple Local Laboratories |
|
|
|
| |
|
|
|
|
|
C. Views of Sponsors on the Use of Central Laboratories |
|
|
|
| |
|
|
|
|
|
D. Establishing Central Laboratories in Europe |
|
|
|
| |
|
|
|
|
|
VII. Performance Measures for Zeneca's Clinical Pathology Laboratory |
|
|
|
| |
|
|
|
|
|
A. Sample Transport Time |
|
|
|
| |
|
|
|
|
|
B. Result Reporting Times |
|
|
|
| |
|
|
|
|
|
C. Completeness of Results Database |
|
|
|
| |
|
|
|
|
|
D. Competitive Charges |
|
|
|
| |
|
|
|
|
|
VIII. Direct Cost and Indirect Cost Benefits |
|
|
|
| |
|
|
|
|
|
A. Added Value Associated with Efficient Data Processing |
|
|
|
| |
|
|
|
|
|
B. Hidden Cost Benefit Associated with Reduced Development Time |
|
|
|
| |
|
|
|
|
|
IX. Zeneca Laboratory's Hidden Cost Benefit |
|
|
|
| |
|
|
|
|
|
A. More Efficient Use of Laboratory Resources |
|
|
|
| |
|
|
|
|
|
B. Economy of Scale and Common Resources |
|
|
|
| |
|
|
|
|
|
C. Reduced Reporting Time |
|
|
|
| |
|
|
|
|
|
X. Establishing Relationships and Avoiding Problems |
|
|
|
| |
|
|
|
|
|
A. Relationships |
|
|
|
| |
|
|
|
|
|
B. Operational Pretrial Checks at Central Laboratories |
|
|
|
| |
|
|
|
|
|
C. Avoiding Problems |
|
|
|
| |
|
|
|
|
|
XI. Laboratory Relationships and Data Management |
|
|
|
| |
|
|
|
|
|
A. Effective Relationships Within Zeneca |
|
|
|
| |
|
|
|
|
|
B. Effective Relationships Within Europe |
|
|
|
| |
|
|
|
|
|
C. Patient Review and Database Management |
|
|
|
| |
|
|
|
|
|
XII. What of the Future? |
|
|
|
| |
|
|
|
|
|
References |
|
|
|
| |